These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25348193)

  • 1. Prognostic implications of receptor discordance between primary and recurrent breast cancer.
    Matsumoto A; Jinno H; Murata T; Seki T; Takahashi M; Hayashida T; Kameyama K; Kitagawa Y
    Int J Clin Oncol; 2015 Aug; 20(4):701-8. PubMed ID: 25348193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer.
    Shiino S; Kinoshita T; Yoshida M; Jimbo K; Asaga S; Takayama S; Tsuda H
    Clin Breast Cancer; 2016 Aug; 16(4):e133-40. PubMed ID: 27268749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
    Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
    Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.
    Erdem GU; Altundag K; Ozdemir NY; Sahin S; Demirci NS; Karatas F; Bozkaya Y; Aytekin A; Tasdemir V; Aslan AC; Sever AR; Zengin N
    J BUON; 2017; 22(2):365-376. PubMed ID: 28534357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis.
    Dieci MV; Barbieri E; Piacentini F; Ficarra G; Bettelli S; Dominici M; Conte PF; Guarneri V
    Ann Oncol; 2013 Jan; 24(1):101-8. PubMed ID: 23002281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
    Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
    Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.
    Aurilio G; Disalvatore D; Pruneri G; Bagnardi V; Viale G; Curigliano G; Adamoli L; Munzone E; Sciandivasci A; De Vita F; Goldhirsch A; Nolè F
    Eur J Cancer; 2014 Jan; 50(2):277-89. PubMed ID: 24269135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
    Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
    Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
    Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
    Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Finn RS; Press MF; Dering J; O'Rourke L; Florance A; Ellis C; Martin AM; Johnston S
    Clin Cancer Res; 2014 Feb; 20(3):736-43. PubMed ID: 24198242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
    Amir E; Clemons M; Purdie CA; Miller N; Quinlan P; Geddie W; Coleman RE; Freedman OC; Jordan LB; Thompson AM
    Cancer Treat Rev; 2012 Oct; 38(6):708-14. PubMed ID: 22178456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.
    Liedtke C; Broglio K; Moulder S; Hsu L; Kau SW; Symmans WF; Albarracin C; Meric-Bernstam F; Woodward W; Theriault RL; Kiesel L; Hortobagyi GN; Pusztai L; Gonzalez-Angulo AM
    Ann Oncol; 2009 Dec; 20(12):1953-8. PubMed ID: 19596702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discrepancies in Hormone Receptor and HER2 Expression between Malignant Serous Effusions and Paired Tissues from Primary or Recurrent Breast Cancers.
    Nikas IP; Lim S; Im SA; Lee KH; Lee DW; Lee H; Ryu HS
    Pathobiology; 2024; 91(3):169-179. PubMed ID: 37816333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.